Table 4.
Selected ongoing immunotherapy-based clinical trials for SMARCB1-deficient sarcoma.
| NCT Identifier/ Study Name |
Drugs | Clinical Trial Phase | Population | Estimated Enrollment | Primary Completion Date |
Location |
|---|---|---|---|---|---|---|
|
NCT04741438/ RAR-Immune |
Nivolumab + Ipilimumab | III | Metastatic or unresectable advanced sarcoma of rare subtype including ES and chordoma | 96 | February 2025 | Centre Léon Bérard, Lyon, France |
| NCT04416568 | Nivolumab + Ipilimumab | II | Relapsed or refractory INI1-negative cancers in children and young adults from 6 months to 30 years | 45 | October 2023 | Dana-Farber Cancer Institute, United States, Massachusetts |
|
NCT04705818/ CAIRE |
Durvalumab + Tazemetostat | II | Distinct cohorts of solid tumors including soft-tissue sarcoma and metastatic solid tumor with positive interferon gamma signature and/or presence of TLS | 173 | October 2022 | Multiple French Cancer Institute |
|
NCT04095208/ CONGRATS |
Nivolumab + Relatlimab | II | Advanced non-resectable/metastatic soft tissue sarcoma with high-level of tertiary lymphoid structures | 67 | March 2022 | Multiple French Cancer Institute |
Abbreviations: ES: epithelioid sarcoma; TLS: tertiary lymphoid structure.